Molecule

S2019 

Biological Activity:
Sarpogrelate hydrochloride is a selective 5-HT2A receptor antagonist to 5-HT2A, 5-HT2C and 5-HT2B receptors with pKi of 8.52, 7.43 and 6.57, respectively.Sarpogrelate hydrochloride reveals selectivity over 5-HT1, 5-HT3, 5-HT4 H1, H2, M3, α1-adrenergic, α2-adrenergic and β-adrenergic receptors. Additionally, Sarpogrelate hydrochloride displays cardioprotective activity in vivo. [1] Sarpogrelate hydrochloride improves vascular function in patients with peripheral arterial disease. Sarpogrelate hydrochloride blocks serotonin-induced platelet aggregation, and has applications in the treatment of many diseases including diabetes mellitus, Buerger’s disease, Raynaud’s disease, coronary artery disease, angina pectoris, and atherosclerosis. [2]References on Sarpogrelate HCl[1] J Cardiovasc Pharmacol., 2007, 49(4):221-7[2] http://en.wikipedia.org/wiki/Sarpogrelate, ,

S5451 

Biochem/physiol Actions
Sarapogrelate hydrochloride is a potent and selective 5-HT2A receptor antagonist. It exhibits analgesic effects in numerous animal studies.1

S142300 

Sarpogrelate hydrochloride is a potent and selective 5-HT2A receptor antagonist and is used as an antiplatelet agent. It has been reported to increase erythrocyte deformability and suppress shear stress-induced hemolysis.